Recent headlines highlighted the Trump administration may be threatening to impose steep tariffs, potentially as high as 200%1, on imported prescription drugs. This is part of a broader initiative to reshore pharmaceutical manufacturing to the United States.
While this may sound alarming, there is no immediate cause for concern. At this time, these tariffs have not yet been enacted and, according to both Commerce Secretary Lutnick and President Trump’s statements, any tariff changes would not take effect for at least 12 to 18 months. This would place the possible implementation window between the latter half of 2026 or beginning of 2027. More details are expected to be forthcoming from the Trump administration.
The Benecard team is actively monitoring this development and we will continue to keep our healthcare professionals and plan sponsors apprised of any tariff policy announcements or news related to this matter from the Trump administration.
Ready to discuss how these strategies can work for your clients?
Contact us today at (800) 734-9528 or talktous@benecard.com to discuss how Benecard is helping employers tackle rising drug trends.
Sources:
1200% drug tariffs loom as Trump pushes reshoring of pharma manufacturing
